MS Infusion Therapy Update with Q&A on COVID-19 Impact

RELEASED: March 23, 2020

EXPIRES: April 30, 2021


Carrie M. Hersh, DO, MSc
Staff Neurologist
Cleveland Clinic
Lou Ruvo Center for
Brain Health
Las Vegas, NV

Amy Perrin Ross,
Neuroscience Program
Loyola University Medical Center
Maywood, IL

Why Attend?

Treatment selection and modification in MS can be a complex, daunting
problem for MS care providers. Enjoy active discussion with your
colleagues and get expert insight into optimizing outcomes for your
patients on infusible MS therapies!

Join us to discuss thought-provoking, real-world cases with your peers and a clinical expert in MS.

Explore solutions to your questions about:

  • Applying currently available treatments and guideline recommendations to your practice
  • Establishing a collaborative relationship between the multidisciplinary MS care team and the patient and their care partners
  • Managing clinical challenges of infusible MS therapie

Who Should Attend?

Physicians, nursing professionals, pharmacists, and other members of
the healthcare team who care for patients with MS.

Learning Objectives

Upon completion of this activity, learners should be better able to:

  • ANALYZE the mechanisms of action and therapeutic targets for available infusible disease-modifying therapies (DMTs) as part of the therapeutic decision-making process
  • INDIVIDUALIZE infusible therapies based on safety and efficacy data, current guidelines, and patient preferences
  • MONITOR individuals for tolerability, response to therapy, and infusion-related reactions
  • DISCUSS infusion procedures, potential adverse effects, and post-infusion care recommendations with people receiving infusible DMTs and their families


In support of improving patient care, this enduring activity has been planned
and implemented by the Consortium of Multiple Sclerosis Centers
(CMSC) and Spire Learning. CMSC is jointly accredited by the
Accreditation Council for Continuing Medical Education (ACCME),
the Accreditation Council for Pharmacy Education (ACPE), and the American
Nurses Credentialing Center (ANCC), to provide continuing education for the
healthcare team.

Physician Credit Designation Statement
The CMSC designates this enduring activity for a maximum of 1.5AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation Statement
The CMSC designates this enduring activity for a maximum of 1.5 contact hours of
continuing nursing education.

Pharmacist Credit Designation Statement
The Consortium of Multiple Sclerosis Centers (CMSC) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education and will award 1.5 contact hours (.15 CEUs) to pharmacists who (1) participate in the enduring activity, and (2) complete the evaluation form. The Universal Activity Number (UAN) for this activity is (JA4008165-9999-20-023-H01-P). This is a knowledge-based activity.


The opinions expressed in this educational activity are those of the faculty and do not represent those of the CMSC or Spire Learning. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information


This educational activity may contain discussion of published and/or investigational uses of therapies that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, participants are encouraged to consult appropriate resources for any product or device mentioned in this program.


There is no fee to participate in this activity. In order to receive your CME certificate, you must:
  • Complete the preassessment questions prior to the start of the program
  • Participate in the program
  • Complete the postassessment and evaluation at the end of the program
Certificates will be sent within 4 weeks of participation.

Per regulatory guidelines, the educational grant used to support this activity may only be used for medical professionals attending the presentation. Our grant funding does not allow for participation by non-healthcare providers and/or guests.

Jointly provided by

Supported by an educational grant from Genentech, Inc. and Sanofi Genzyme